Loading…

Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii

Summary Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This stu...

Full description

Saved in:
Bibliographic Details
Published in:Mycoses 2012-03, Vol.55 (2), p.156-160
Main Authors: Saribas, Zeynep, Yurdakul, Pinar, Cetin-Hazirolan, Gulsen, Arikan-Akdagli, Sevtap
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3
cites cdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3
container_end_page 160
container_issue 2
container_start_page 156
container_title Mycoses
container_volume 55
creator Saribas, Zeynep
Yurdakul, Pinar
Cetin-Hazirolan, Gulsen
Arikan-Akdagli, Sevtap
description Summary Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to >99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.
doi_str_mv 10.1111/j.1439-0507.2011.02050.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_922500430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>922500430</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS1ERZfCX0C-wSVhbCd2cuCAFiiVtuVSVOBiebN28eLYqZ3Abn89Dlv2iPDFM57vjfX0EMIESpLP621JKtYWUIMoKRBSAs11uXuEFsfBY7SAlrFCVCBO0dOUtgBEtJQ_QaeUcN7UtF6g-wtv3KR9p3EwOOk49Th4bD3-accYcJpSp4fRrq2z4x6POo3W386s7r5bHzrlN9YnbELEy7neKDyoqIZkXUg24fx2HNxO1jmrYx9yb5-hE6Nc0s8f7jP0-cP76-XHYvXp_GL5dlV02QoUBozgG8K0aWrD25orRiraCdpB1YAxBEhrGCFCVaZaC2ibSjOuDAWua7FW7Ay9POwdYribsgHZ22zKOeV1mJJsKa0BKgaZfPVPkgBtgFHGWUabA9rFkFLURg7R9iruMyTnjORWzlHIOQo5ZyT_ZCR3Wfri4Zdp3evNUfg3lAy8OQC_rNP7_14sL78u5yrri4PeplHvjnoVf0gumKjlzdW5bMW7b6svN9eyYb8By_ev_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1028032363</pqid></control><display><type>article</type><title>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Saribas, Zeynep ; Yurdakul, Pinar ; Cetin-Hazirolan, Gulsen ; Arikan-Akdagli, Sevtap</creator><creatorcontrib>Saribas, Zeynep ; Yurdakul, Pinar ; Cetin-Hazirolan, Gulsen ; Arikan-Akdagli, Sevtap</creatorcontrib><description>Summary Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to &gt;99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.</description><identifier>ISSN: 0933-7407</identifier><identifier>EISSN: 1439-0507</identifier><identifier>DOI: 10.1111/j.1439-0507.2011.02050.x</identifier><identifier>PMID: 21668525</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antifungal Agents - metabolism ; Antifungal Agents - pharmacology ; Aspergillosis ; Aspergillosis - microbiology ; Aspergillus ; Aspergillus - drug effects ; Aspergillus - growth &amp; development ; Aspergillus - isolation &amp; purification ; Blood Proteins - metabolism ; Candida ; Candida - drug effects ; Candida - growth &amp; development ; Candida - isolation &amp; purification ; Candida guilliermondii ; Candida parapsilosis ; Candidiasis ; Candidiasis, Invasive - microbiology ; Caspofungin ; Clinical isolates ; Drugs ; echinocandins ; Echinocandins - metabolism ; Echinocandins - pharmacology ; Humans ; in vitro susceptibility testing ; micafungin ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Protein Binding ; Serum ; Serum proteins</subject><ispartof>Mycoses, 2012-03, Vol.55 (2), p.156-160</ispartof><rights>2011 Blackwell Verlag GmbH</rights><rights>2011 Blackwell Verlag GmbH.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</citedby><cites>FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21668525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saribas, Zeynep</creatorcontrib><creatorcontrib>Yurdakul, Pinar</creatorcontrib><creatorcontrib>Cetin-Hazirolan, Gulsen</creatorcontrib><creatorcontrib>Arikan-Akdagli, Sevtap</creatorcontrib><title>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</title><title>Mycoses</title><addtitle>Mycoses</addtitle><description>Summary Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to &gt;99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.</description><subject>Antifungal Agents - metabolism</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillosis</subject><subject>Aspergillosis - microbiology</subject><subject>Aspergillus</subject><subject>Aspergillus - drug effects</subject><subject>Aspergillus - growth &amp; development</subject><subject>Aspergillus - isolation &amp; purification</subject><subject>Blood Proteins - metabolism</subject><subject>Candida</subject><subject>Candida - drug effects</subject><subject>Candida - growth &amp; development</subject><subject>Candida - isolation &amp; purification</subject><subject>Candida guilliermondii</subject><subject>Candida parapsilosis</subject><subject>Candidiasis</subject><subject>Candidiasis, Invasive - microbiology</subject><subject>Caspofungin</subject><subject>Clinical isolates</subject><subject>Drugs</subject><subject>echinocandins</subject><subject>Echinocandins - metabolism</subject><subject>Echinocandins - pharmacology</subject><subject>Humans</subject><subject>in vitro susceptibility testing</subject><subject>micafungin</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Protein Binding</subject><subject>Serum</subject><subject>Serum proteins</subject><issn>0933-7407</issn><issn>1439-0507</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkUFv1DAQhS1ERZfCX0C-wSVhbCd2cuCAFiiVtuVSVOBiebN28eLYqZ3Abn89Dlv2iPDFM57vjfX0EMIESpLP621JKtYWUIMoKRBSAs11uXuEFsfBY7SAlrFCVCBO0dOUtgBEtJQ_QaeUcN7UtF6g-wtv3KR9p3EwOOk49Th4bD3-accYcJpSp4fRrq2z4x6POo3W386s7r5bHzrlN9YnbELEy7neKDyoqIZkXUg24fx2HNxO1jmrYx9yb5-hE6Nc0s8f7jP0-cP76-XHYvXp_GL5dlV02QoUBozgG8K0aWrD25orRiraCdpB1YAxBEhrGCFCVaZaC2ibSjOuDAWua7FW7Ay9POwdYribsgHZ22zKOeV1mJJsKa0BKgaZfPVPkgBtgFHGWUabA9rFkFLURg7R9iruMyTnjORWzlHIOQo5ZyT_ZCR3Wfri4Zdp3evNUfg3lAy8OQC_rNP7_14sL78u5yrri4PeplHvjnoVf0gumKjlzdW5bMW7b6svN9eyYb8By_ev_A</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Saribas, Zeynep</creator><creator>Yurdakul, Pinar</creator><creator>Cetin-Hazirolan, Gulsen</creator><creator>Arikan-Akdagli, Sevtap</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</title><author>Saribas, Zeynep ; Yurdakul, Pinar ; Cetin-Hazirolan, Gulsen ; Arikan-Akdagli, Sevtap</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antifungal Agents - metabolism</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillosis</topic><topic>Aspergillosis - microbiology</topic><topic>Aspergillus</topic><topic>Aspergillus - drug effects</topic><topic>Aspergillus - growth &amp; development</topic><topic>Aspergillus - isolation &amp; purification</topic><topic>Blood Proteins - metabolism</topic><topic>Candida</topic><topic>Candida - drug effects</topic><topic>Candida - growth &amp; development</topic><topic>Candida - isolation &amp; purification</topic><topic>Candida guilliermondii</topic><topic>Candida parapsilosis</topic><topic>Candidiasis</topic><topic>Candidiasis, Invasive - microbiology</topic><topic>Caspofungin</topic><topic>Clinical isolates</topic><topic>Drugs</topic><topic>echinocandins</topic><topic>Echinocandins - metabolism</topic><topic>Echinocandins - pharmacology</topic><topic>Humans</topic><topic>in vitro susceptibility testing</topic><topic>micafungin</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Protein Binding</topic><topic>Serum</topic><topic>Serum proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saribas, Zeynep</creatorcontrib><creatorcontrib>Yurdakul, Pinar</creatorcontrib><creatorcontrib>Cetin-Hazirolan, Gulsen</creatorcontrib><creatorcontrib>Arikan-Akdagli, Sevtap</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Mycoses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saribas, Zeynep</au><au>Yurdakul, Pinar</au><au>Cetin-Hazirolan, Gulsen</au><au>Arikan-Akdagli, Sevtap</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii</atitle><jtitle>Mycoses</jtitle><addtitle>Mycoses</addtitle><date>2012-03</date><risdate>2012</risdate><volume>55</volume><issue>2</issue><spage>156</spage><epage>160</epage><pages>156-160</pages><issn>0933-7407</issn><eissn>1439-0507</eissn><abstract>Summary Echinocandins are antifungal drugs used for the treatment of invasive candidiasis and aspergillosis. They bind to serum proteins within a rate of 96 to &gt;99%. The effect of serum on in vitro echinocandin susceptibility tests of certain Candida and Aspergillus species was reported. This study was performed to determine the effect of human serum on in vitro susceptibility testing of echinocandins for clinical isolates of Candida parapsilosis and Candida guilliermondii, the species which generally have higher minimum inhibitor concentrations compared with other Candida species. One hundred C. parapsilosis and 20 C. guilliermondii isolates were included in the study. The susceptibility tests of caspofungin, micafungin and anidulafungin were performed using microdilution method, either in the presence or absence of 50% human serum, according to the Clinical and Laboratory Standards Institute (CLSI) M27‐A3 guidelines. It was demonstrated that human serum significantly affects the in vitro susceptibility results of echinocandins for C. parapsilosis and C. guilliermondii isolates, mostly yielding an increase in MICs. The most prominent fold changes were for micafungin and anidulafungin in C. parapsilosis, and for anidulafungin in C. guilliermondii isolates. Serum influences the in vitro echinocandin susceptibility in C. parapsilosis and C. guilliermondii. The mechanism and clinical significance of this in vitro change need to be clarified.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21668525</pmid><doi>10.1111/j.1439-0507.2011.02050.x</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0933-7407
ispartof Mycoses, 2012-03, Vol.55 (2), p.156-160
issn 0933-7407
1439-0507
language eng
recordid cdi_proquest_miscellaneous_922500430
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects Antifungal Agents - metabolism
Antifungal Agents - pharmacology
Aspergillosis
Aspergillosis - microbiology
Aspergillus
Aspergillus - drug effects
Aspergillus - growth & development
Aspergillus - isolation & purification
Blood Proteins - metabolism
Candida
Candida - drug effects
Candida - growth & development
Candida - isolation & purification
Candida guilliermondii
Candida parapsilosis
Candidiasis
Candidiasis, Invasive - microbiology
Caspofungin
Clinical isolates
Drugs
echinocandins
Echinocandins - metabolism
Echinocandins - pharmacology
Humans
in vitro susceptibility testing
micafungin
Microbial Sensitivity Tests
Minimum inhibitory concentration
Protein Binding
Serum
Serum proteins
title Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A29%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20serum%20on%20in%20vitro%20susceptibility%20testing%20of%20echinocandins%20for%20Candida%20parapsilosis%20and%20Candida%20guilliermondii&rft.jtitle=Mycoses&rft.au=Saribas,%20Zeynep&rft.date=2012-03&rft.volume=55&rft.issue=2&rft.spage=156&rft.epage=160&rft.pages=156-160&rft.issn=0933-7407&rft.eissn=1439-0507&rft_id=info:doi/10.1111/j.1439-0507.2011.02050.x&rft_dat=%3Cproquest_cross%3E922500430%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4390-f0f76d13ef85f6956a3142c72c0480ff1019f3117a4f4b70984e36af206e57ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1028032363&rft_id=info:pmid/21668525&rfr_iscdi=true